Prevalence, Diagnosis and Outcomes of Treatment for Primary Aldosteronism
Publication date: Available online 5 December 2019Source: Best Practice &Research Clinical Endocrinology &MetabolismAuthor(s): Yuhong Yang, Martin Reincke, Tracy Ann WilliamsAbstractPrimary aldosteronism (PA) is the most common potentially curable form of hypertension. The overproduction of aldosterone leads to an increased risk of cardiovascular and cerebrovascular events as well as adverse effects to the heart and kidney and psychological disorders. PA is mainly caused by unilateral aldosterone excess due to an aldosterone-producing adenoma or bilateral excess due to bilateral adrenocortical hyperplasia. The diagnostic work-up of PA comprises three steps: screening, confirmatory testing and differentiation of unilateral surgically-correctable forms from medically treated bilateral PA. These specific treatments can mitigate or reverse the increased risks associated with PA. Herein we summarise the prevalence, outcomes and current and future clinical approaches for the diagnosis of primary aldosteronism.
Purpose of review In 2013, the association between T-Box factor 4 (TBX4) variants and pulmonary arterial hypertension (PAH) has first been described. Now – in 2020 – growing evidence is emerging indicating that TBX4 variants associate with a wide spectrum of lung disorders. Recent findings TBX4 variants are enriched in both children and adults with PAH. The clinical phenotype associated with a TBX4 variant seems to be milder than that in other PAH-associated gene mutations. Further, TBX4 variants have increasingly been associated with a variety of clinical and histopathological phenotypes, including lethal...
Publication date: Available online 1 April 2020Source: Social Science &MedicineAuthor(s): Patricia East, Jenalee Doom, Erin Delker, Estela Blanco, Raquel Burrows, Paulina Correa-Burrows, Betsy Lozoff, Sheila Gahagan
CONCLUSION: The hypertension burden would decrease from 244.5 million persons to 127.5-182.3 million persons in China if the two-visit strategy was applied. PMID: 32224596 [PubMed - as supplied by publisher]
Conditions: Hypertension, Essential; β-hydroxybutyrate Intervention: Other: dietary restriction (salt restriction) Sponsor: Sulaiman AlRajhi Colleges Not yet recruiting
Condition: Resistant Hypertension Interventions: Drug: Spironolactone; Drug: Amiloride Sponsor: Yonsei University Not yet recruiting
Conditions: COVID-19; Hypertension; Cardiovascular Diseases Intervention: Sponsor: Societa Italiana dell'Ipertensione Arteriosa Recruiting
Contributors : Lesha Zhang ; Bing ShenSeries Type : Expression profiling by high throughput sequencingOrganism : Rattus norvegicusWe utilized high-throughput sequencing and subsequent signaling pathway analyses to find 2 fold change or greater upregulated expression of 230 transcripts and downregulated expression of 165 transcripts in basilar artery smooth muscle cells derived from rats fed a high-salt diet compared with those from control rats.
Authors: Siegel JD, Ko CJ Abstract Diltiazem is a calcium-channel blocker commonly used for the treatment of hypertension. Common adverse effects include dizziness, headache, and edema. Fewer than 20 cases of diltiazem-associated photodistributed hyperpigmentation have been reported in the literature. Here, we present the case of a 71-year-old woman with new-onset facial hyperpigmentation 6 months after initiating treatment with diltiazem. PMID: 32226335 [PubMed - in process]
Update: On April 1, 2020, the FDA requested manufacturers to withdraw all prescription and over-the-counter (OTC) ranitidine drugs (Zantac, others) from the market immediately, due to the presence of a contaminant known as N-Nitrosodimethylamine (NDMA). Although the FDA did not observe unacceptable levels of NDMA in many of the samples they tested, they have determined that the impurity in some ranitidine products increases over time and when stored at higher than room temperatures. As a result of this recall, ranitidine products will no longer be available for prescription or OTC use in the US. The FDA is also advising co...
The EMA have stated that the speculation that ACE-inhibitors or ARBs treatment can make infections worse in the context of COVID-19 is not currently supported by clinical evidence, and they state that there is currently no reason for patients to stop these treatments.